Background
Treatment of stroke episodes in acute phase (AIS) in Poland is financed under hospital stay. Patient hospitalization due to stroke is reimbursed within specific Diagnostic Related Group (DRG): A58 to A51, depending on detailed diagnosis and treatment. At the time of this analysis, treatment of AIS with mechanical thrombectomy (MT) was not reimbursed in Poland. However, according to expert opinion, there are few stroke centers in Poland where some patients are treated with MT.
Objective
To estimate the impact of MT, using a stent retriever, on budget of public payer's in Poland. Additionally, as treatment of long-term stroke consequences require patient's co-payment, a perspective of public payer+patient was considered.
Methodology Results

Population
Estimated size of target population is 8,748 in 2017 and 9,792 in 2018. This include all patients who will be treated with IV rt-PA (regardless of MT availability) and all patients who will be treated with BSC other than IV rt-PA (all available for MT). In current scenario none of patient is treated with MT+BSC. In predicted scenario MT will be added to BSC in 514 patients in 1 st and 1,150 in 2 nd year of reimbursement.
General Assumptions
Analysis was performed from two perspectives in a 2-year time horizon (2017) (2018) . It was assumed that MT, using a stent retriever, will be added to best standard care (BSC) and patients treated with BSC can be divided into 2 subgroups:
• treated with IV rt-PA (and MT is added to BSC defined as IV rt-PA),
• unsuitable to IV rt-PA (and MT is added to BSC defined as other than IV rt-PA).
For key parameters and assumptions (target population size, prevalence of MT, cost data) one-way sensitivity analysis (OWSA) were performed. 
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Population size
Based on available data presented by NHF as DRG stats [1] it was possible to estimate total number of patients who will be treated with IV rt-PA in subsequent years. In this subgroup of patients MT added to BSC can be applied to a certain percentage of the subgroup. This was calculated based on data received from one stroke center in Poland [2] . Based on these data also number of patients in a subgroup unsuitable to IV rt-PA who can be treated with MT was estimated.
Total number of strokes in 2009-2014 was between 72,489 to 79,102. It was assumed that in subsequent years total number of stroke episodes will be constant at 77,946 patients as in 2014. Percentage of strokes treated with IV rt-PA will be increasing in subsequent years (2015) (2016) (2017) (2018) . Based on linear regression it was estimated on 10.7% in 2017 and 12.0% in 2018.
Prevalence of MT
According to clinical expert opinion there are some limitations that have negative impact on total number of patients who can be treated with MT:
• insufficient number of clinical specialists with experience in treatment of stroke with MT,
• insufficient number of clinical centers providing a non-stop specialist care.
Due to that it was arbitrary assumed that in 1 st year of MT reimbursement only 50% of available patients will receive such treatment. In 2 nd year all available patients will be treated with MT+BSC.
Cost data
Following cost categories were included: cost of MT+BSC or BSC alone, cost of adverse events management and cost of health state.
Detailed cost data were taken directly from economic analysis or were estimated based on the results of economic analysis (COST-EFFECTIVENESS ANALYSIS OF MECHANICAL THROMBECTOMY IN ACUTE PHASE OF ISCHEMIC STROKE (IN POLAND)).
• 20% of patients need 2 thrombectomies per stroke episode,
• costs of adverse events treatment were estimated based on detailed data on safety and cost of adverse events management.
• costs of health states were estimated based on detailed data on effectiveness and mortality and result of Polish cost study [3] .
Expenditures
In current scenario estimated NHF expenditures in target population will be ca 151. It can be seen that despite of increase in total expenditures there are savings in categories related to health states. This is due to fact that adding MT to BSC is more effective than BSC alone and cost related to treatment of long-term consequences of stroke are lower.
OWSA indicate on variability of incremental results ranging from 19.1 to 45.0 mPLN in 2017 and from 42.7 to 65.4 mPLN in 2018.
Data received from one stroke center in Poland contain information on patients with stroke treated between January 2013 and April 2016: total number of stroke episodes, total number of performed MT added to BSC defined as IV rt-PA or other treatment. Assuming that 12% of strokes will be treated with IV rt-PA the percentage of patients treated with MT + BSC in a subgroup of patients treated with IV rt-PA was estimated as 7.64%. Those patients are 62.2% of all treated with MT added to BSC. 
Cost
Conclusions
Our findings suggest that positive decision on reimbursement of mechanical thrombectomy, using a stent retriever, will cause increase in public payer (or public payer+patient) expenditures for treatment of AIS. However, there is a possibility for some savings in long-term time horizon.
